NK-Cell Leukemia Recruiting Phase 0 Trials for Brentuximab vedotin (DB08870)

Also known as: Aggressive NK-cell leukemia / NK-cell leukaemia / Natural killer-cell leukemia / Natural killer-cell leukaemia / Aggressive NK cell leukemia

IndicationStatusPhase
DBCOND0115144 (NK-Cell Leukemia)Recruiting0
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03719105Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/LymphomaTreatment